eli lilly tirzepatide news today recency 3 Lilly's triple-acting obesity drug hits goal in Phase trial Eli Lilly's Phase 3 data – Company of the Year 2025:

outer thighs middle third is the target

In April 2024, the EMA's Pharmacovigilance Risk Assessment Committee concluded there is no causal association between GLP-1 receptor agonists and suicidal or self-injurious thoughts, though monitoring continues

[2] [22] 20.4 kilocalories per gram compared to the 4 kilocalories per gram found in regular sugar

Always consult a qualified physician before starting any GLP-1 medication

Tirzepatide has been shown in clinical studies to support meaningful weight loss in many patients, particularly in adults who have struggled with traditional diet and exercise alone

Instead, its benefits lie in promoting overall health, which might help your hormones function better